Treatment of rats with Jiangzhi Capsule improves liquid fructose-induced fatty liver: modulation of hepatic expression of SREBP-1c and DGAT-2 by Yuanyang Zhao et al.
Zhao et al. J Transl Med  (2015) 13:174 
DOI 10.1186/s12967-015-0529-6
RESEARCH
Treatment of rats with Jiangzhi Capsule 
improves liquid fructose-induced fatty liver: 
modulation of hepatic expression of SREBP-1c 
and DGAT-2
Yuanyang Zhao1, Yongquan Pan2, Yifan Yang3, Robert Batey4, Jianwei Wang5* and Yuhao Li3*
Abstract 
Background: Jiangzhi Capsule is an Australian listed patented traditional Chinese medicine and has been used 
for management of lipid abnormalities over the past 10 years. To obtain a better understanding regarding Jiangzhi 
Capsule, the present study investigated the effects and underlying mechanisms of Jiangzhi Capsule on chronic 
fructose overconsumption-induced lipid abnormalities.
Methods: Male rats were treated with liquid fructose in their drinking water over 14 weeks. Jiangzhi Capsule was 
co-administered (once daily, by oral gavage) during the last 7 weeks. Indexes of lipid and glucose homeostasis were 
determined enzymatically, by ELISA and/or histologically. Gene expression was analyzed by real-time PCR, Western 
blot and/or immunohistochemistry.
Results: Treatment with Jiangzhi Capsule (100 mg/kg) attenuated fructose-induced excessive triglyceride 
accumulation and Oil Red O-stained area in the liver. This effect was accompanied by amelioration of 
hyperinsulinemia. There was no significant difference in intakes of fructose and chow, and body weight between 
fructose control and fructose Jiangzhi Capsule-treated groups. Mechanistically, Jiangzhi Capsule downregulated 
fructose-stimulated hepatic overexpression of sterol regulatory element binding protein (SREBP)-1/1c at the mRNA 
and protein levels. Accordingly, the SREBP-1c downstream genes, acetyl-CoA carboxylase-1 and stearoyl-CoA 
desaturase-1, were also inhibited. In addition, acyl-coenzyme A:diacylglycerol acyltransferase (DGAT)-2 expression 
at the mRNA and protein levels in the liver was also inhibited after Jiangzhi Capsule treatment. In contrast, Jiangzhi 
Capsule affected neither carbohydrate response element binding protein, peroxisome proliferator-activated receptor 
(PPAR)-gamma and DGAT-1, nor PPAR-alpha and its target genes.
Conclusions: These findings demonstrate the anti-steatotic action of Jiangzhi Capsule in fructose-fed rats, and 
modulation of hepatic SREBP-1c and DGAT-2 involved in hepatic de novo synthesis of fatty acids and triglyceride, 
respectively. Our findings provide an evidence-based and mechanistic understanding of Jiangzhi Capsule supporting 
its application for the prevention and/or treatment of fatty liver and its associated disorders in clinical practice.
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Background
Nonalcoholic fatty liver disease has become an important 
public health problem due to its high prevalence, poten-
tial progression to severe liver disease, and association 
with cardiometabolic abnormalities [1, 2]. Fatty liver, the 
hallmark of nonalcoholic fatty liver disease, is linked to 
obesity, insulin resistance and type 2 diabetes [2]. How-
ever, there is no effective therapy currently approved by 
The Food and Drug Administration of the United States 
of America for treatment of this common disorder. Tra-
ditional Chinese medicine (TCM) has been used to treat 
liver disease in China since ancient times. Numerous 
Chinese herbs and active components have been tested 
for treatment of nonalcoholic fatty liver disease. Evi-
dence from randomized controlled trials has suggested 
the efficacy and safety of TCM therapies in the treatment 
of nonalcoholic fatty liver disease [3]. TCM herbs have 
predominately been used clinically in the form of for-
mulas containing an average of ten herbs [3]. However, 
relatively few evidence-based investigations have been 
undertaken to examine the therapeutic activities and the 
underlying mechanisms of action associated with TCM 
formulas for nonalcoholic fatty liver disease.
Excessive fat accumulation in the liver can occur as 
a result of numerous factors among which increased fat 
synthesis plays a pivotal role [2]. Hepatic de novo fatty 
acid synthesis may contribute to excessive lipid accumu-
lation in the liver with the enzymes responsible for fatty 
acid synthesis being transcriptionally regulated [2]. Sterol 
regulatory element-binding protein (SREBP)-1c is the 
principal inducer of de novo hepatic lipogenesis by modu-
lating lipogenic enzymes, such as acetyl-CoA carboxylase 
(ACC) and stearoyl-CoA desaturase (SCD)-1 [2, 4]. In 
contrast, acyl-coenzyme A:diacylglycerol acyltransferase 
(DGAT)s are the enzymes those catalyze the final step and 
rate-limiting reaction in triglyceride synthesis. DGAT-1 
likely plays a role in intestinal repackaging of free fatty 
acids, whereas DGAT-2 is predominately expressed in the 
liver and catalyzes the final step of triglyceride biosynthe-
sis [2]. Recent studies have demonstrated that DGAT-2 
plays an important role in hepatocyte triglyceride synthe-
sis, thereby contributing to hepatic steatosis [5, 6]. Reduc-
tion of DGAT-2 expression by antisense oligonucleotide 
attenuates hepatic steatosis in high fat diet-induced obese 
mice and ob/ob mice [7], and in high fat diet-fed rats [8].
Jiangzhi Capsule is an Australian listed patented TCM 
formula (AUST L 134445) and has been used for man-
agement of lipid abnormalities over the past 10 years. It 
is composed of 13 herbs: Radix Astragali, Poria, Folium 
Nelumbinis, Rhizoma Alisma, Fructus Crataegi, Fructus 
Chaenomelis, Radix et Rhizoma Salviae Miltiorrhizae, 
Radix et Rhizoma Notoginseng, Pollen Typhae, Rhizoma 
et Radix Polygoni cuspidati, Herba Taraxaci, Radix 
Polygoni multiflori and Fructus Ligustri Lucidi. Many of 
individual herbs in this formula, such as Rhizoma Alisma 
[9], Radix Salviae Miltiorrhizae [10, 11], Radix Notogin-
seng [12–14] and Fructus Ligustri Lucidi [15] have been 
reported to regulate glucose and lipid metabolism and/or 
to protect the liver against injuries. Kwon et al. [16] found 
that the formula consisting of Astragalus membrana-
ceus, Crataegus pinnatiida, Alisma orientale, Salvia 
miltiorrhiza, Morus alba and Pueraria lobata attenu-
ated alcohol-induced fatty liver and liver damage in rats. 
Treatment with Fructus Crataegi decreased hepatic 
SREBP-1c mRNA expression in apolipoprotein E-defi-
cient mice [17]. Emodin, an active component contained 
in both Radix Polygoni multiflori and Rhizoma et Radix 
Polygoni cuspidati ameliorated high fat diet-induced 
excessive hepatic triglyceride accumulation, accompa-
nied by a downregulation of hepatic SREBP-1c protein 
expression in rats [18]. We have recently demonstrated 
that oleanolic acid, one of the prominent active com-
ponents contained in Fructus Ligustri Lucidi, improves 
fructose-induced fatty liver via the hepatic SREBP-1c 
pathway [19]. On the other hand, emodin has also been 
noted to decrease DGAT-1 content within in vitro mod-
els of steatosis hepatic L02 cell [20] in addition to reports 
highlighting water extracts of Radix Polygoni multiflori 
can decrease hepatic DGAT activity in high fat diet-fed 
rats [21]. Oleanolic acid has also been noted to inhibit 
DGAT activity in rat liver microsomes [22]. The tanshi-
nones (cryptotanshinone, 15,16-dihydrotanshinone I, 
tanshinone IIA and tanshinone I) isolated from Radix 
Salviae Miltiorrhiza also showed inhibitory effect on 
DGAT activity in rat liver [23]. Whilst studies on the indi-
vidual herbal components provide preliminary evidence, 
there is, however, a lack of evidence-based knowledge in 
the metabolic effects and the underlying mechanisms of 
Jiangzhi Capsule.
Fructose has now become a major constituent of our 
modern diet with chronic overconsumption increas-
ing developmental risk of fatty liver, dyslipidemia, insu-
lin resistance and obesity in animals and humans [4, 
24]. Research has shown that sugar-sweetened nonalco-
holic beverages, such as soft drinks, appear as the major 
source of fructose for all classes of age considered with 
the exception of children younger than 6 years and adults 
older than 50  years [4]. In the present study, we tested 
the effects of Jiangzhi Capsule on liquid fructose-induced 
lipid abnormalities and further investigated the underly-
ing mechanisms in rats.
Methods
Preparation and identification of Jiangzhi Capsule
The raw herbs for Jiangzhi Capsule were purchased from 
Guangdong Yifang Pharmaceutical Co., Ltd, China, and 
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identified by the botanist Dr. Dawen Zhao. The voucher 
specimens were deposited in Guangdong Yifang Pharma-
ceutical Co., Ltd, China. Radix et Rhizoma Notoginseng 
(Panax notoginseng (Burk.) F. H. Chen, voucher speci-
men no. S0020GZYJ106, 5%) was ground into find pow-
der. Radix Astragali (Astragalus membranaceus (Fisch.) 
Bge. Var. mongholicus (Bge.) Hsiao, voucher specimen 
no. H0300/GZYJ118, 8%), Poria (Poria cocos (Schw.) 
Wolf, voucher specimen no. F0070/BJZY100, 8%), Folium 
Nelumbinis (Nelumbo nucifera Gaertn., voucher speci-
men no. H0100/GZYJ170, 3%), Rhizoma Alisma (Alisma 
orientalis (Sam.) Juzep., voucher specimen no. Z0030/
BJZY083, 8%), Fructus Crataegi (Crataegus pinnatiida 
Bge. var. major N. E. Br., voucher specimen no. S0150/
GZYJ173, 10%), Fructus Chaenomelis (Chaenomeles 
speciosa (Sweet) Nakai, voucher specimen no. M0160/
GZYJ022, 6%), Radix et Rhizoma Salviae miltiorrhizae 
(Salvia miltiorrhiza Bge., voucher specimen no. D0100/
BJZY032, 10%), Pollen Typhae (Typha angustifolia L., 
voucher specimen no. P0050/GZYJ182, 6%), Rhizoma et 
Radix Polygoni cuspidati (Polygonum Cuspidatum Sieb. 
et Zucc., voucher specimen no. H0113/BJZY135, 10%), 
Herba Taraxaci (Taraxacum mongolicum Hand.-Mazz., 
voucher specimen no. P0040/GZYJ142, 10%), Radix 
Polygoni multiflori (Polygortum multiflorum Thunb., 
voucher specimen no. H0360/BJZY063, 8%) and Fructus 
Ligustri lucidi (Ligustrum lucidum Ait., voucher speci-
men no. N0080/GZYJ138, 8%) were ground into crude 
powder and extracted with water for two times (10 vol-
umes of water for 2 h boiling and 7 volumes of water for 
1 h boiling). The combined filtrate was evaporated under 
reduced pressure below 50°C. The yield of the extract was 
28%. The powdered Radix et Rhizoma Notoginseng and 
the extract were completely mixed to produce Jiangzhi 
Capsule used in the present study. For quality control, 
Jiangzhi Capsule was identified by HPLC process similar 
to that described in the Chinese Pharmacopoeia (Ver-
sion 1, 2010). Briefly, HPLC profiles were performed on 
an Agilent 1100 ZG-0090 HPLC instrument with Agi-
lent Chimstation System. The chromatography was car-
ried out on an Agilent XDB-C18 5  μm 250  ×  4.6  mm 
(for determination of ginsenoside Rg1, ginsenoside 
Rb1 and notoginsenoside R1) or Purospher-star 5  μm 
150 × 4.6 mm (for salvianolic acid B determination) col-
umn. The sample injection volume was 10 µl. The mobile 
phase for salvianolic acid B determination was consist 
of methanol, acetonitrile, formic acid and water (ratio 
of 30:10:1:59 respectively), while determination of gin-
senoside Rg1, ginsenoside Rb1 and notoginsenoside R1 
was a gradient consisting of a mixture of water and ace-
tonitrile (0–40 min, 80:20; 40–50 min, 80 → 70:20 → 30; 
50–74  min, 70:30; 74–84  min, 70  →  20:30  →  80; 
84–100 min, 20:80). Pure salvianolic acid B, ginsenoside 
Rg1, ginsenoside Rb1 and notoginsenoside R1 (pur-
chased from National Institutes for Food and Drug Con-
trol, Beijing, China) were used as external standards. 
Peak areas were quantified at 286 nm for salvianolic acid 
B, and at 203  nm for ginsenoside Rg1, ginsenoside Rb1 
and notoginsenoside R1.
Animals and treatment protocols
All animal procedures were conducted according to 
international, national and institutional rules regarding 
animal experimentation, and approved by the Animal 
Ethics Committee, Chongqing Medical University, China.
Male Sprague–Dawley rats weighing 210–230  g and 
the standard chow were supplied by the Laboratory 
Animal Center, Chongqing Medical University, China. 
Rats were housed in a temperature controlled facility 
(21 ± 1°C, 55 ± 5% relative humidity) with a 12-h light/
dark cycle. Animals were allowed free access to water and 
the standard chow for at least 1 week prior to starting the 
experiments.
Fructose in drinking water used for the present study 
has been described previously [19, 25–28]. Thirty-three 
rats were divided initially into two groups: water con-
trol free access to water (n = 6), and fructose group free 
access to 10% fructose solution (w/v, preparation every 
day) (n  =  27). This fructose group had continued free 
access to 10% fructose solution for the duration of the 
study but was further divided into the following three 
groups (n = 9) 7 weeks after study commencement: fruc-
tose control, fructose Jiangzhi Capsule 25  mg/kg and 
fructose Jiangzhi Capsule 100  mg/kg. Animals in Jiang-
zhi Capsule-treated groups were administered Jiangzhi 
Capsule 25 or 100  mg/kg (suspended in 5% Gum Ara-
bic solution, gavage once daily), respectively. The rats in 
the corresponding water- and fructose-control groups 
received vehicle (5% Gum Arabic) alone. All rats had free 
access to the standard chow. To avoid stress and increase 
monitoring accuracy of fructose intake, only three rats 
were housed in a cage at any given time. The consumed 
chow and fructose solution were measured per three rats 
daily and the intake of fructose was calculated. At the 
endpoint of the experiment, rats were deprived of chow 
and fructose solution, but still had free access to water 
overnight. Blood samples were collected by retroorbital 
venous puncture under ether anesthesia at 9:00–12:00 
am for determination of plasma concentrations of total 
cholesterol (kit from Kexin Institute of Biotechnology, 
Shanghai, China), triglyceride (Triglyceride-E kit, Wako, 
Osaka, Japan), non-esterified fatty acid (NEFA) (NEFA-C 
kit, Wako, Osaka, Japan), glucose (kit from Kexin Insti-
tute of Biotechnology, Shanghai, China) and insulin (kit 
from Morinaga Biochemical Industries, Tokyo, Japan). 
Animals were immediately weighed and euthanised by 
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prompt dislocation of the neck vertebra. The liver was 
collected and weighed, and the ratio of liver weight to 
body weight calculated. Segments of liver were snap 
frozen in liquid nitrogen and stored at −80°C for subse-
quent determination of gene/protein expression, and tri-
glyceride and total cholesterol contents.
Determination of triglyceride and total cholesterol 
contents in liver
Triglyceride and total cholesterol contents in liver were 
determined as described previously [29]. Briefly, 100 mg 
of tissue was homogenized and extracted with 2  ml of 
isopropanol. After centrifugation (3,000 rpm), the triglyc-
eride and total cholesterol contents in supernatants were 
determined enzymatically (Wako, Osaka, Japan).
Histological examination
A portion of liver was fixed with 10% formalin and 
embedded in paraffin. Three-micron sections were cut 
and stained with hematoxylin and eosin for examina-
tion of liver histology (BX-51, Olympus Corporation, 
Tokyo, Japan). To further confirm lipid droplet accumu-
lation, 6-μm frozen sections were stained with Oil Red 
O. Forty fields in three individual sections were randomly 
selected, and the Oil Red O-stained area and the total 
tissue area were measured using an ImageJ 1.43 analyz-
ing system. The ratio of the Oil Red O-stained area to the 
total tissue area was calculated (%).
Real‑time PCR
Real time PCR was performed as described previously 
[25, 26]. Total RNA was isolated from the livers of indi-
vidual rats using TRIzol (Takara, Dalian, China). cDNA 
was synthesized using M-MLV RTase cDNA Synthesis Kit 
(Takara, Dalian, China) according to the manufacturer’s 
instructions. Real time PCR was performed with the CFX 
96 Real Time PCR Detection System (Biorad Laboratories 
Inc, Hercules, CA, USA) using the SYBR® Premix Ex Taq™ 
II (Takara, Dalian, China). The sequences of primers are 
shown in Additional file 1: Table S1. The gene expression 
from each sample was analysed in duplicates and normal-
ized against the internal control gene β-actin. Levels in 
water control rats were arbitrarily assigned a value of 1.
Western blot
Western blot was performed as described previously 
[25]. Total and nuclear proteins were prepared individu-
ally from livers using the kits for tissue and nuclear pro-
tein extraction (Pierce Biotechnology, Rockford, IL, 
USA), according to the manufacturer’s instructions. Pro-
tein concentration was determined using the Bradford 
method (Bio Rad Laboratories, Hercules, CA, USA) using 
bovine serum albumin as a standard. Protein (30 μg) was 
subjected to SDS-PAGE analysis on a 10% gel, and then 
electrotransferred onto polyvinylidene fluoride mem-
brane (Amersham, Buckinghamshire, UK). SREBP-1 and 
DGAT-2 (dilution 1:200, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) were detected with a goat polyclonal anti-
body and rabbit polyclonal antibody, respectively. Detec-
tion of signals was performed using the ECL Western blot 
detection kit (Pierce Biotechnology, Rockford, IL, USA) 
with anti-goat and anti-rabbit horseradish peroxidase-con-
jugated IgG (dilution 1:5,000, Santa Cruz Biotechnology, 
Santa Cruz, CA, USA) as second antibody, respectively. 
Polyclonal rabbit Lamin A/C antibody (dilution 1:1,000, 
Cell Signaling Technologies, Beverly, MA, USA) was used 
as loading control to normalize the signal obtained for 
nuclear SREBP-1 protein. Mouse monoclonal β-actin anti-
body (dilution 1:1,000, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) was used as loading control to normalize 
the signal obtained for DGAT-2 protein. The immunore-
active bands were visualized by autoradiography and the 
density was evaluated using ImageJ 1.43. Levels in water 
control rats were arbitrarily assigned a value of 1.
Immunohistochemistry
A portion of liver was fixed with 4% paraformaldehyde, 
dehydrated and embedded in paraffin. Sections (3  μm) 
were dewaxed in xylene, rehydrated in ethanol and treated 
with 3% H2O2 in absolute methanol for 30 min. Next, sec-
tions were immersed in citrate buffer (pH = 6.0), boiled 
for 10 min and cooled down at room temperature. Slides 
were blocked with normal goat serum for 30  min and 
then incubated with rabbit polyclonal anti-DGAT2 anti-
bodies (dilution 1:200, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) at 4°C overnight. Next, the samples were 
submitted to ABC (kit from Zhongshan Golden Bridge 
Biotechnology, Beijing, China) (biotin: 1  h; streptavidin: 
30 min, 37°C), followed by incubation with DAB (kit from 
Zhongshan Golden Bridge Biotechnology, Beijing, China) 
for 1  min. Counterstaining was performed with May-
er’s hematoxylin. Omission of the primary antibody was 
served as the negative control.
Data analysis
All results are expressed as means  ±  SEM. Data were 
analyzed by ANOVA using the StatView software, and 
followed by The Student–Newman–Keuls test to locate 
the differences between groups. P < 0.05 was considered 
to be statistically significant.
Results
Identification of the contents of some active components 
in Jiangzhi Capsule
It has been reported that Radix Salviae miltiorrhizae [10, 
11, 30] and Radix Notoginseng [12–14] have pleiotropic 
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pharmacological activities. In the present study, some 
typical active components contained in Radix Salviae 
miltiorrhizae and Radix Notoginseng of Jiangzhi Cap-
sule were identified and quantified by HPLC as follows: 
salvianolic acid B, 0.533% (retention time 10.755  min), 
ginsenoside Rg1, 0.787% (retention time 37.289  min), 
ginsenoside Rb1, 0.640% (retention time 71.332 min) and 
notoginsenoside R1, 0.199% (retention time 24.869 min).
Intakes of fructose and chow, and body weight in rats
The results showed that fructose control rats ate less 
chow, compared to water controls (Figure  1b). There 
was no significant difference in intakes of fructose (Fig-
ure  1a) and chow (Figure  1b) between fructose control 
and fructose Jiangzhi Capsule-treated groups. Water 
control rats were heavier than fructose controls; there 
was no difference in body weight between fructose con-
trol and fructose Jiangzhi Capsule groups before treat-
ments commenced (Figure  1c). There was no difference 
in body weights between groups at the endpoint of the 
experiment (Figure 1c); the body weight gain in fructose 
control intended to increase compared to water control, 
which tended to decrease after Jiangzhi Capsule treat-
ment (Figure 1d).
Blood biochemical parameters in rats
Compared to water control rats, fructose controls 
showed higher plasma concentrations of total choles-
terol (Figure  2a), triglyceride (Figure  2b) and insulin 
(Figure  2e), whereas there was no significant difference 
in plasma NEFA (Figure 2c) and glucose (Figure 2d) con-
centrations between water control and fructose control. 
Jiangzhi Capsule at both 25 and 100 mg/kg significantly 
suppressed the insulin increase (Figure  2e). However, 
Jiangzhi Capsule showed minimal effect on plasma con-
centrations of total cholesterol, triglyceride, NEFA and 
glucose (Figure 2a–d).
Liver‑associated parameters in rats
Although fructose feeding did not significantly affect liver 
weight (Figure  3a) and the ratio of liver weight to body 
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Figure 1 Intakes of fructose (a) and laboratory chow (b), body weight (c) and body weight gain (d) in water control, fructose control and fructose 
Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. Con control, JZL JZ 25 mg/kg, JZH JZ 100 mg/kg.
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and triglyceride (Figure 3d) contents were increased after 
fructose feeding. Accordingly, fructose feeding increased 
vacuolization (Figure  4b) and Oil Red O staining area 
(Figure 5b), indicative of fructose-induced excess hepatic 
lipid droplet accumulation. Jiangzhi Capsule treatment 
(both dosages) did not alter liver weight (Figure 3a), ratio 
of liver weight to body weight (Figure 3b) or hepatic total 
cholesterol content (Figure  3c). However, Jiangzhi Cap-
sule substantially decreased hepatic triglyceride content 
(Figure 3d). This coincided with vacuolization (Figure 4c, 
d) and Oil Red O staining area (Figure 5c, d) in the liver 
being also significantly reduced.
Hepatic gene/protein expression in rats
As the treatment with Jiangzhi Capsule at 100  mg/kg 
showed more pronounced effects on hepatic triglyceride 
accumulation, comparisons in gene/protein expression 
are restricted to water control, fructose control, and fruc-
tose Jiangzhi Capsule 100 mg/kg groups.
By real-time PCR 14-week fructose feeding increased 
hepatic expression of mRNAs encoding SREBP-1c 
(Figure  6a), ACC-1 (Figure  6c), SCD-1 (Figure  6d) and 
DGAT-2 (Figure  7b). The increased contents of nuclear 
SREBP-1 protein (Figure  6b) and DGAT-2 protein (Fig-
ure 7c) were further demonstrated by Western blot anal-
ysis. Immunohistochemical staining results also showed 
upregulated DGAT-2 protein expression in fructose con-
trol compared to water control (Figure 7d). Seven-week 
Jiangzhi Capsule treatment downregulated mRNA lev-
els of SREBP-1c (Figure  6a), ACC-1 (Figure  6c), SCD-1 
(Figure 6d) and DGAT-2 (Figure 7b). The results of pro-
tein expression further confirmed the suppression of 
SREBP-1 (Figure 6b) and DGAT-2 (Figure 7c, d) by Jiang-
zhi Capsule treatment.
Also with regards to the liver, fructose feeding did not 
significantly alter mRNA levels of DGAT-1 (Figure  7a), 
ChREBP (Figure  8a), PPAR-γ (Figure  8b), PPAR-α (Fig-
ure  8c), acyl-CoA oxidase (ACO) (Figure  8e) and CD36 
(Figure 8f ), but downregulated carnitine palmitoyltrans-
ferase (CPT)-1a expression (Figure 8d). Jiangzhi Capsule 

























































































































Figure 2 Plasma total cholesterol (a), triglyceride (b), NEFA (c), glucose (d) and insulin (e) concentrations in water control, fructose control and 
fructose Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. Con control, JZL JZ 25 mg/kg, JZH JZ 100 mg/kg.






















































































Figure 3 Liver weight (a), the ratio of liver weight to body weight (b), liver total cholesterol content (c) and liver triglyceride content (d) in water 
control, fructose control and fructose Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. Con control, JZL JZ 
25 mg/kg, JZH JZ 100 mg/kg.
Water Con Fructose Con
Fructose JZL Fructose JZH
(a) (b)
(c) (d)
Figure 4 Representative images showing histology of liver (hematoxylin and eosin-staining, a–d, ×200) in water control, fructose control and 
fructose Jiangzhi Capsule (JZ)-treated rats. Con ontrol, JZL JZ 25 mg/kg, JZH JZ 100 mg/kg.
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Discussion
The present results clearly demonstrated that treatment 
of rats with Jiangzhi Capsule decreased fructose feeding-
induced excess hepatic triglyceride accumulation and 
increased vacuolization and Oil Red O staining area in 
the livers. However, Jiangzhi Capsule did not affect chow 
and fructose intakes and body weight, and had minimal 
effect on plasma concentrations of total cholesterol, tri-
glyceride, NEFA and glucose. Therefore, these findings 
suggest a specific anti-steatotic effect of Jiangzhi Capsule 
in rats.
Fructose, by providing large amounts of hepatic triose-
phosphate as precursors for fatty acid synthesis, is highly 
lipogenic [4]. Recent findings suggest that the increase 
in hepatic de novo lipogenesis is one of the major pro-
viders of lipids in fructose-induced fatty liver [4, 31]. A 
high-fructose diet has been shown to induce the expres-
sion of the transcription factor SREBP-1c [4]. In addition, 
fructose consumption may also activate another hepatic 
transcription factor ChREBP, which upregulates the 
expression of hepatic lipogenic genes responsible for fatty 
acid synthesis [4]. In the present study, Jiangzhi Capsule 
treatment substantially suppressed fructose-stimulated 
hepatic overexpression of both SREBP-1c mRNA and 
nuclear SREBP-1 protein. Accordingly, the overexpres-
sion of SREBP-1c downstream genes ACC-1 and SCD-1 
was also downregulated, however, hepatic ChREBP 
expression remained unchanged after Jiangzhi Capsule 
treatment. Thus, these results suggest that modulation 
of hepatic SREBP-1c-mediated expression of the genes 
responsible for hepatic de novo fatty acid synthesis con-
tributes to the anti-steatotic effect of Jiangzhi Capsule in 
rats.
Recently, we have demonstrated that mangiferin, a 
prominent component contained in many anti-obese 
and anti-diabetic herbs, ameliorates fructose-induced 




























Figure 5 Representative images showing hepatic lipid accumulation (Oil Red O staining, a–c, ×200) and Oil Red O stained area (d) in water 
control, fructose control and fructose Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. Con control, JZH JZ 
100 mg/kg.
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fatty liver by suppressing hepatic DGAT-2 expression 
in spontaneously hypertensive rats [28]. In the present 
study, treatment with Jiangzhi Capsule also significantly 
inhibited hepatic DGAT-2 expression at the mRNA and 
protein levels, but was without effect on DGAT-1 expres-
sion in fructose-fed rats. Thus, these findings suggest 
that inhibition of hepatic DGAT-2 is also responsible for 
Jiangzhi Capsule-elicited attenuation of fructose-induced 
excessive hepatic triglyceride accumulation.
Reduction in hepatic fatty acid oxidation and increased 
fatty acid uptake into liver appear to have only minor 
roles in hepatic triglyceride deposition [2]. PPAR-α, pre-
dominantly expressed in the liver and, to a lesser extent, 
in the heart and muscle, has a crucial role in control-
ling fatty acid oxidation and uptake through direct tran-
scriptional control of the genes, such as CPT1a, ACO 
and CD36 [32]. The induction of fatty acid oxidation by 
PPAR-α activation improves plasma lipid profiles. In a 
variety of mouse models, PPAR-α agonists lower plasma 
triglycerides, reduce adiposity and improve hepatic and 
muscular steatosis [32]. In contrast, PPAR-γ is predomi-
nantly expressed in adipose tissue and normally at low 
level in liver [32]. PPAR-γ is associated with regulation 
of the genes encoding molecules that promote a com-
bination of lipid storage and lipogenesis [32]. In mice, 
activation of PPAR-γ in liver appears to contribute to 
the development of hepatic steatosis [33, 34]. It has been 
reported that the contribution of de novo lipogenesis to 
fructose-induced hypertriglyceridemia is small [35]. Fur-
thermore, research findings suggest a DGAT-2-induced 
disconnection between liver and circulating triglyceride 
levels. In transgenic mice overexpressing hepatic DGAT-
2, there were increased liver triglyceride content and 
reduced circulating triglyceride level [36, 37]. In the pre-
sent study, treatment with Jiangzhi Capsule did not alter 
hepatic expression of PPAR-α, CPT-1a, ACO, CD36 and 
PPAR-γ in fructose-fed rats. Thus, our findings in gene 































































































1 2 3 4 5 6
Figure 6 Hepatic expression of mRNAs encoding sterol regulatory element-binding protein (SREBP)-1c (a), acetyl-CoA carboxylase (ACC)-1 (c) 
and stearoyl-CoA desaturase (SCD)-1 (d), and protein of nuclear SREBP-1 (b lanes 1, 2 water control; lanes 3, 4 fructose control; lanes 5, 6 fructose JZ 
100 mg/kg) in water control, fructose control and fructose Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. 
Con control, JZH JZ 100 mg/kg.
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Figure 7 Hepatic expression of mRNAs encoding acyl-coenzyme A:diacylglycerol acyltransferase (DGAT)-1 (a) and DGAT-2 (b), and protein of 
DGAT-2 by Western blot (c lanes 1, 2 water control; lanes 3, 4 fructose control; lanes 5, 6 fructose JZ 100 mg/kg) and immunohistochemical staining 
(d) in water control, fructose control and fructose Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. Con 



























































































































Figure 8 Hepatic expression of mRNAs encoding carbohydrate response element binding protein (ChREBP) (a), peroxisome proliferator-activated 
receptor (PPAR)-γ (b), PPAR-α (c), carnitine palmitoyltransferase (CPT)-1a (d), acyl-CoA oxidase (ACO) (e) and CD36 (f) in water control, fructose con-
trol and fructose Jiangzhi Capsule (JZ)-treated rats. Data are means ± SEM (n = 6–9 each group). *P < 0.05. Con control, JZH JZ 100 mg/kg.
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PPAR-α and PPAR-γ pathways in the anti-steatotic effect 
of Jiangzhi Capsule in rats. A consideration may be that 
modulation of hepatic de novo lipogenesis via the SREBP-
1c and DGAT-2 pathways by Jiangzhi Capsule is insuffi-
cient to improve fructose-induced hypertriglyceridemia.
Although hepatic steatosis is strongly associated with 
the development of insulin resistance, it remains unclear 
whether insulin resistance causes the excessive accumu-
lation of triglyceride in the liver, or whether the increase 
in triglyceride itself or of metabolite intermediates may 
play a causal role in the development of insulin resistance 
[2]. Some studies have shown that the accumulation of 
intrahepatic lipids precedes the state of insulin resistance 
[2]. In the present study, the anti-steatotic effect of Jiang-
zhi Capsule treatment was accompanied by pronounced 
amelioration of fructose-induced hyperinsulinemia. 
Further investigations are needed to determine whether 
Jiangzhi Capsule improves insulin resistance through 
attenuation of excessive hepatic triglyceride accumula-
tion or whether the improvement of fatty liver is partially 
secondary to the amelioration of insulin resistance.
Conclusions
Our present results demonstrate the anti-steatotic action 
of Jiangzhi Capsule in fructose-fed rats and modulation 
of hepatic SREBP-1c and DGAT-2 that are involved in 
hepatic de novo synthesis of fatty acids and triglyceride, 
respectively. Our findings provide an evidence-based and 
mechanistic understanding of Jiangzhi Capsule for the 
prevention and/or treatment of fatty liver and its associ-
ated disorders in clinic.
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